Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era. But even as the billions pile up, Regeneron isn't entirely happy with ...

The organization that was set to operate a supervised injection site in Charlottetown says it was "disheartened" and "surprised" to learn the province wouldn't be continuing the project as planned.

Bristol Myers Squibb has continued its ruthless cost-cutting push, dropping plans to commercialize a rival to Dupixent despite meeting its phase 3 goals and pumping the brakes on a would-be ...

The organization that was set to operate a supervised injection site in Charlottetown says it was "disheartened" and "surprised" to learn the province wouldn't be continuing the project as planned.

Despite Eylea's market challenges, Dupixent's strong performance and ... who need only receive around three injections of Vabysmo per annum, against six injections of Eylea per annum, for an ...

One day after a subcutaneous injection into the left thigh, she developed a mildly pruritic eruption on the right thigh, at the site of a previous injection. Etanercept (Enbrel ®) is an ...

One primary reason is the strong performance and potential of Dupixent, which is expected to partially counterbalance the uncertainties surrounding Eylea. The expected growth in Dupixent’s ...

Zacks Rank #3 (Hold) stock ARM Holdings (ARM) is a dominant player in the semiconductor industry due to its energy-efficient designs, which are critical to the function of smartphones, laptops ...

Sanofi and Regeneron have celebrated a pair of positive clinical trials in inflammatory skin disorders with blockbuster immunology therapy Dupixent that could both lead to new indications for the ...

The CEO discussed the success of Dupixent and the remarkable achievement of over $13 billion in global sales in 2024, highlighting its commercial advantage and setting a milestone for Sanofi.

P.E.I.'s chief public health officer says the province has decided to pause the establishment of a supervised injection site and instead prioritize strengthening its existing harm reduction ...

You would think that Arm, which arguably has been the vanguard in the smartphone and PC industry push for improved power efficiency, would double down on that strategy in its plans for 2025.